iNOPulse for COVID-19

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 1, 2020

Primary Completion Date

June 1, 2021

Study Completion Date

July 15, 2021

Conditions
COVID-19HypoxemiaHypoxemic Respiratory Failure
Interventions
DRUG

Inhaled nitric oxide (iNO)

iNO Pulse 250 mcg/kg ideal body weight (IBW)/hour

DRUG

Nitrogen gas

250 mcg/kg ideal body weight (IBW)/hour

DRUG

Oxygen gas

Supplemental oxygen administered via nasal cannula

Trial Locations (1)

33125

University of Miami Hospitals & Clinics, Miami

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bellerophon Therapeutics

UNKNOWN

lead

Roger Alvarez

OTHER